Corrigendum to “The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies” [Vaccine 30 (2012) 886–892]  by Ambrose, Christopher S. et al.
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The authors regret that in the original published paper entitled “The efﬁcacy of intranasal live attenuated inﬂuenza vaccine in children
 through 17 years of age: A meta-analysis of 8 randomized controlled studies,” there were errors in Fig. 2. The Bracco Neto 2009 study was
rroneously included in the “B (Original classiﬁcation)” and “B (B variants as dissimilar)” sections. The Vesikari 2006 study was erroneously
xcluded from the “B (B variants as dissimilar)” section. These errors have been corrected in the revised ﬁgure and do not affect the integrity
f the results or modify the conclusions.
The revised ﬁgure is reproduced here.
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The authors would like to apologise for any inconvenience caused.
DOI of original article: http://dx.doi.org/10.1016/j.vaccine.2011.11.104.
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